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RESEARCH
Experimental non‑alcoholic steatohepatitis 
in Göttingen Minipigs: consequences of high 
fat‑fructose‑cholesterol diet and diabetes
Camilla Schumacher‑Petersen1, Berit Østergaard Christoffersen2, Rikke Kaae Kirk2, Trine Pagh Ludvigsen2, 
Nora Elisabeth Zois3,4, Henrik Duelund Pedersen1,5, Mogens Vyberg6,7 and Lisbeth Høier Olsen1* 
Abstract 
Background: Non‑alcoholic fatty liver disease (NAFLD) is the most common liver disease in humans, and ranges 
from steatosis to non‑alcoholic steatohepatitis (NASH), the latter with risk of progression to cirrhosis. The Göttingen 
Minipig has been used in studies of obesity and diabetes, but liver changes have not been described. The aim of this 
study was to characterize hepatic changes in Göttingen Minipigs with or without diabetes, fed a diet high in fat, fruc‑
tose, and cholesterol to see if liver alterations resemble features of human NAFLD/NASH.
Methods: Fifty‑four male castrated minipigs (age 6 to 7 months) were distributed into four groups and diet‑fed for 13 
months. Groups were: lean controls fed standard diet (SD, n = 8), a group fed high fat/fructose/cholesterol diet (FFC, 
n = 16), a group fed high fat/fructose/cholesterol diet but changed to standard diet after 7 months (diet normaliza‑
tion, FFC/SD, n = 16), and a streptozotocin‑induced diabetic group fed high fat/fructose/cholesterol diet  (FFCDIA, 
n = 14). At termination, blood samples for analyses of circulating biomarkers and liver tissue for histopathological 
assessment and analyses of lipids and glycogen content were collected.
Results: In comparison with SD and FFC/SD, FFC and  FFCDIA pigs developed hepatomegaly with increased content 
of cholesterol, whereas no difference in triglyceride content was found. FFC and  FFCDIA groups had increased val‑
ues of circulating total cholesterol and triglycerides and the hepatic circulating markers alkaline phosphatase and 
glutamate dehydrogenase. In the histopathological evaluation, fibrosis (mainly located periportally) and inflammation 
along with cytoplasmic alterations (characterized by hepatocytes with pale, granulated cytoplasm) were found in FFC 
and  FFCDIA groups compared to SD and FFC/SD. Interestingly, FFC/SD also had fibrosis, a feature not seen in SD. Only 
two FFC and three  FFCDIA pigs had > 5% steatosis, and no hepatocellular ballooning or Mallory–Denk bodies were 
found in any of the pigs.
Conclusions: Fibrosis, inflammation and cytoplasmic alterations were characteristic features in the livers of FCC and 
 FFCDIA pigs. Overall, diabetes did not exacerbate the hepatic changes compared to FFC. The limited presence of the 
key human‑relevant pathological hepatic findings of steatosis and hepatocellular ballooning and the variation in the 
model, limits its use in preclinical research without further optimisation.
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Background
It has recently been estimated that human non-alcoholic 
fatty liver disease (NAFLD) has a 25% worldwide preva-
lence and is expected to become the major reason for 
liver transplantations in the western world [1, 2].
NAFLD ranges from simple steatosis to non-alco-
holic steatohepatitis (NASH), the latter characterized 
by additional inflammation, hepatocellular hydropic 
degeneration (also called ballooning) and eventually Mal-
lory–Denk bodies associated with fibrosis which can lead 
to cirrhosis. Type 2 diabetes is considered the primary 
risk factor for progression of simple steatosis to advanced 
stages of NASH [3]. In addition, NAFLD seems to be a 
central risk factor for the development of cardiovascular 
disease [4] and other complications also related to diabe-
tes [5, 6]. It can be difficult to diagnose NAFLD given that 
clinical signs usually are sparse even at late stages where 
liver damage is substantial; and changes in circulating 
liver biomarkers are often non-specific. Histopathologi-
cal evaluation of samples from liver biopsies is still con-
sidered the gold standard for diagnosing the disease even 
though new non-invasive alternatives are emerging [7].
The hepatic disease mechanisms are still largely 
unknown, and effective treatment modalities are lacking. 
Therefore, various animal models have been investigated 
to help unravel the pathogenesis and for testing new 
pharmaceutical drug candidates or lifestyle interventions. 
Diet- or chemically-induced rodent models of NASH/
NAFLD have mainly been used, and several mouse 
strains exist with spontaneous or transgenic mutations 
that pinpoint different signalling pathways [8, 9]. Larger 
animal models have also been examined, as anatomy, 
physiology or simply size can be beneficial depending on 
the research question of interest [10, 11].
Histopathological features resembling NASH in 
humans have been reported in Ossabaw minipigs [10, 
12] fed a diet high in fat, fructose and cholesterol. Oth-
ers have studied Bama minipigs and Microminipigs on 
high fat/high sucrose diet or high fat/high cholesterol 
diet with a supplement of cholic acid, respectively, and 
reported microvesicular steatosis and inflammation, but 
none or limited hepatocellular ballooning and fibrosis 
[11, 13]. The Göttingen Minipig is widely used in stud-
ies of obesity and metabolic syndrome [14–16], but diet-
induced histopathological changes in the liver have not 
been characterized.
In this study, the aim was to investigate the liver 
changes in Göttingen Minipigs fed a diet with high 
content of fat, fructose and cholesterol for over a year. 
Hepatic gross morphology, histopathology and tissue 
content of lipids and glycogen as well as changes in rel-
evant circulating biomarkers were investigated. Further-
more, it was evaluated if diabetes would exacerbate the 
alterations and if a diet change to standard diet would 
limit pathologic changes. The hypothesis was that Göt-
tingen Minipigs fed a diet high in fat, fructose and cho-
lesterol would develop hepatic changes that resemble 
human NAFLD including NASH.
Materials and methods
Study setup and animals
Castrated male Göttingen Minipigs (Ellegaard Göttingen 
Minipigs A/S, Dalmose, Denmark) (n = 54 in total) aged 
6 to 7 months were weight stratified and distributed into 
four groups (Fig.  1a) and fed once daily for 13  months. 
The pigs were part of a larger study (n = 84 in total) 
looking at different aspects of obesity [17] and diabetes 
related complications (two intervention groups were not 
included in the present study). The included groups were: 
lean control pigs (SD, n = 8) fed standard diet (Mini-pig, 
SDS, UK (Table  1)); a group fed high fat/fructose/cho-
lesterol (2%) diet (5B4L) for the first 5 months and sub-
sequently changed to a similar diet with 1% cholesterol 
(9G4U) for the next 8 months [both diets from Test 
 diet®, Missouri, USA (Table  1)] (high fat/fructose/cho-
lesterol, FFC, n = 16); a group fed the same diets as FFC 
for the first 7 months but returned to standard diet the 
last 6 months of the study (diet-normalization, FFC/SD, 
n = 16) and a diabetic group fed a high fat/fructose/cho-
lesterol (1%) diet throughout the study (9G4U)  (FFCDIA, 
n = 14). Details of diet feeding in the four groups can 
be seen in Fig.  1b. Straw was used as bedding material, 
and the animals had access to fresh drinking water at all 
times.
The diabetic group had type 1-like diabetes induced 
with streptozotocin administered intravenously once 
daily for three consecutive days [18] (modified version of 
Gerrity et al. optimized for Göttingen Minipigs; 60 mg/
kg bodyweight). Diabetic animals were treated once daily 
with a long acting insulin (insulin glargine,  Lantus®, 
Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, 
Germany) subcutaneously immediately after the daily 
diet ration was offered in the morning; targeting fasting 
morning glucose levels of 14–16 mM.
Three to eight weeks before termination, blood for 
quantification of circulating biomarkers and intravenous 
glucose tolerance test (IVGTT) were sampled in plain 
serum tubes and EDTA coated tubes. Blood samples 
were kept on ice for maximum 30  min (EDTA) or kept 
at room temperature (serum) for 1  h before centrifu-
gation for 10  min, 2000×g at 4  °C. After centrifugation 
EDTA plasma and serum were pipetted into appropri-
ate tubes and stored at − 80  °C. The IVGTT procedure 
including calculation of intravenous glucose tolerance 
index  (KG) and area under the curve for insulin response 
(AUC Insulin) were performed as previously described 
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[17]. Homeostasis model assessment of insulin resist-
ance (HOMA-IR) was calculated as fasting insulin (µU/
mL)  ×  fasting glucose (mM)/22.5 [19] in all animals 
except for the diabetic animals since their fasting glucose 
values were also influenced by the long-acting insulin 
glargine. Total body fat percentage (BF%) was estimated 
a
b
Fig. 1 Flow diagram of the distribution of minipigs and details of diet feeding within each group. a Fifty‑four Göttingen Minipigs were included in 
the study and eleven were terminated early. The reasons for early termination are provided under each group. The two cases of procedure‑related 
complications occurred during investigations of other end points (unrelated to the present study) performed in the same animals. b Overview and 
details of the diet feeding in each of the four groups over the study period. BW body weight, FFC high fat/fructose/cholesterol diet group, FFCDIA 
diabetic group, FFC/SD diet‑normalization group, PT premature termination, SD lean control group
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using dual energy x-ray absorptiometry (DEXA) (Lunar 
prodigy, GE Healthcare, Brøndby, Denmark) 1 to 6 weeks 
before termination. All animals were euthanized by 
exsanguination in general anaesthesia (mixture of zolaz-
epam, tiletamine, ketamine, xylazine and butorphanol as 
previously described by Pedersen et  al. [20]). After ter-
mination, the liver was removed and weighed. A sample 
(1 × 1 × 1–2  cm) from each of the four main liver lobes 
[Lobus hepatis sinister medialis (SM) and lateralis (SL), 
Lobus hepatis dexter medialis (DM) and lateralis (DL)] 
was collected mid-lobe and fixed in 10% neutral buffered 
formalin for 24–32 h, processed, and embedded in par-
affin. From one liver lobe (SM) samples were obtained, 
snap frozen in liquid nitrogen and kept at −  80  °C or 
cryo fixated in optimum cutting temperature compound 
(OCT) (Tissue-Tek® O.C.T. Compound,  Sakura® Finetek, 
Alphen aan den Rijn, The Netherlands) on dry ice. Ani-
mals were fasted overnight before blood sampling, DEXA 
assessment, and termination.
Analysis of circulating biomarkers
Plasma concentrations of alkaline phosphatase (ALP), 
alanine transaminase (ALT), aspartate transaminase 
(AST), glutamate dehydrogenase (GLDH), total choles-
terol (TC), triglycerides (TG), glucose (GLU), fructosa-
mine (FRA), and albumin (ALB) were quantified using 
an autoanalyzer Cobas  6000® (Roche A/S, Hvidovre, 
Denmark). A modified version of a previously described 
method [21] was used for quantification of C-reactive 
protein in serum (CRP).
Biochemical analysis of liver tissue content of triglycerides, 
cholesterol and glycogen
Snap frozen SM liver samples were homogenized as pre-
viously described [22] and the content of cholesterol, 
triglycerides and glycogen were measured by Cobas 
 6000® in duplicates. Six samples were analyzed six times 
for the determination of intra-assay variation.
Histopathological assessment
The liver samples were fixed in neutral buffered forma-
lin for 24–32 h. From each lobe one six mm tissue core 
was punched. The cores were embedded in paraffin in a 
recognisable pattern [tissue micro array (TMA)]. Three 
µm thick sections were cut and routinely stained with 
hematoxylin and eosin (HE), picro-sirius red (PSR), and 
periodic acid-Schiff (PAS) with and without diastase pre-
treatment. Selected elements from the NAFLD activity 
score (NAS) [23] were used to evaluate steatosis (HE), 
fibrosis (PSR) and inflammation (HE). The latter was 
evaluated by the number of inflammatory foci (defined 
as at least 5 extravascular inflammatory cells in a clus-
ter). Cytoplasmic alterations (CA) in the hepatocytes 
(HE) and the glycogen content (PAS) were scored from 
0 (none) to 3 (severe). For all findings, the localization or 
zonal distribution was recorded. In Table 2, an overview 
of the different elements in the qualitative histopatho-
logical assessment is provided. All assessments were 
performed in a blinded manner by one observer and, 
moreover, eight samples were scored three times for the 
determination of intra-observer variation.
Immunohistochemical (IHC) staining using a poly-
clonal goat anti-ionized calcium binding adapter mol-
ecule 1 (Iba1) antibody (Abcam #ab5076) was applied 
to detect macrophages [24]. Antigen retrieval on 
deparaffinized slides was done by microwave heating 
in TEG-buffer pH 9.0 (Ampliqon A/S, Odense, Den-
mark) for 15  min before endogenous peroxidase was 
inhibited with hydrogen peroxide (3%) (Merck, Darm-
stadt, Germany) for 10  min. Both avidin and biotin 
Table 1 Nutritional composition of the three diets used in the study
Percentages are of total energy content
ppm parts per million
a Mini pig, Special Diet Services (SDS), Essex, United Kingdom
b TestDiets®, Missouri, USA
Diet Standarda High fat, fructose, cholesterol (2%) 
(5B4L)b
High fat, fructose, 
cholesterol (1%) 
(9G4U)b
Carbohydrates (%) 74.6 40.8 40.8
Protein (%) 18.6 16.2 16.1
Fat (%) 6.8 43 43
Fructose (%) 5.5 (all sugars) 17.8 18.8
Cholesterol (ppm) ~ 0 20,045 10,045
Methionine (ppm) 1800 3500 3500
Choline (ppm) 784 668 668
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(Dako Biotin blocking system, Dako A/S, Glostrup, 
Denmark) was used for 10  min each for blockage of 
endogenous biotin. Pre-incubation with donkey serum 
(7%) (Jackson Immunoresearch, West Grove PA, USA) 
in Tris-buffered saline (TBS) (Ampliqon A/S, Odense, 
Denmark) + Tween 20 (TBS + T) (Merck, Darmstadt, 
Germany) and skimmed milk (5%) (BD, Kgs. Lyngby, 
Denmark) for blockage of unspecific antibody bind-
ing was performed for 30  min. Primary goat antibody 
against Iba1 (1:1500) (Abcam, Cambridge, UK, #5076) 
was applied for 120 min; thereafter secondary antibody 
(biotinylated donkey-anti-goat 1:1000) (Jackson Immu-
noresearch, West Grove PA, USA, #705-065-147) was 
applied for 30  min. Both antibodies were dissolved in 
a TBS + T + 0.5% skimmed milk solution. ABC-detec-
tion system  (VECTASTAIN®  Elite® ABC-HRP Kit, 
Vector Laboratories, Burlingame, CA, USA) was used 
for 30  min followed by chromogen (DAB + chromo-
gen, Dako A/S, Glostrup, Denmark) for 10 min before 
counterstaining was performed with Mayer’s hema-
toxylin (Sigma-Aldrich/Merck, Darmstadt, Germany). 
Between every step, except blockage of unspecific 
antibody binding, slides were washed with TBS + T. A 
negative control slide was used without primary anti-
body, and two different non-conjugated goat IgG were 
used for check of unspecific staining [‘ChromPure Goat 
IgG’ (1:10,000), Jackson Immunoresearch, West Grove 
PA, USA, #005-000-003 and ‘Normal Goat IgG Control’ 
(1:1000), R&D Systems, Oxon, UK, #AB-108-C].
Also, 10  µm sections from OCT embedded frozen 
blocks from lobe SM were cut and stained with Oil red 
O (ORO) in order to visualize the distribution of lipid 
and confirm steatosis found on HE sections. Image 
analysis software (Visiopharm, Hørsholm, Denmark) 
was used to quantify fibrosis (PSR-VIS), inflamma-
tion (Iba1-VIS) and lipid (ORO-VIS) by measuring the 
stained areas. For all TMAs (PSR-VIS and Iba1-VIS), 
the measured area was adjusted for the number of lob-
ules in order to normalise for the difference in lobular 
diameter. The lobular diameter was estimated as the 
number of all lobules represented (both whole and 
fractioned) per TMA, since all areas of TMAs were 
nearly the same; a low number indicating a larger lobu-
lar diameter. Total tissue area for frozen OCT samples 
Table 2 Overview of elements in the qualitative histopathological assessment
For each element scoring, localization and/or type were recorded
NAS Modified from the NAFLD activity score (NAS) [22], PAS Periodic acid Schiff (glycogen staining)
Elements from human diagnostics Score Type/localization




Macrovesicular, microvesicular or mixed
Zone 1, 2, 3
Fibrosis (NAS) 0: None
1: Perisinusoidal or periportal
2: Perisinusoidal and portal/periportal
3: Bridging
4: Cirrhosis
Subgroups of score 1:
1A: Mild, zone 3, perisinusoidal
1B: Moderate, zone 3, perisinusoidal
1C: Portal/periportal







Hepatocellular ballooning 0: None
1: Few balloon cells
2: Many cells/prominent ballooning
Hydropic degeneration
Mallory–Denk bodies 0: None to rare
1: Many
Other elements Score Localization




Zone 1, 2, 3




Zone 1, 2, 3
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(ORO-VIS) varied in size which led to correction of the 
stained area with total tissue area.
Statistical analysis
Shapiro–Wilk test was used to test whether data were 
normal distributed in groups and due to the majority 
of the evaluated parameters not being normally distrib-
uted, all data were expressed in tables as medians and 
interquartiles.
Differences among the four liver lobes in histopathol-
ogy were investigated by a linear model taking repeated 
measurements into account.
Group differences in basic characteristics, circulating 
biomarkers, liver tissue content, and histopathological 
parametric data were tested using analysis of variance 
(ANOVA) with Welch adjustment for unequal variance 
between groups and Tukey’s correction for multiple com-
parisons. When needed, an appropriate transformation 
of the response variables was performed to obtain vari-
ance homogeneity and normal distribution of residuals in 
the ANOVA analyses. Fisher’s exact test was used to test 
categorical data for group differences.
In addition, linear regression was used to test for asso-
ciations between histopathological data and circulating 
biomarkers or tissue content. Associations between his-
topathological scores were evaluated using Fisher’s exact 
test.
Statistical analyses were performed using SAS 9.4 soft-
ware (SAS Institute Inc., Cary, NC, USA) and the signifi-
cance level was set to p < 0.05. Graphs were created with 
GraphPad Prism (GraphPad Software Inc., La Jolla, CA, 
USA).
Results
Forty-three pigs completed the study. Eleven pigs were 
excluded (Fig.  1a). Five pigs were euthanized accord-
ing to predefined endpoints and six died suddenly: one 
SD (euthanized due to procedure related complications), 
two FFC (one euthanized due to procedure related com-
plications and another died suddenly with a tentative 
diagnosis of circulatory failure with accumulation of ser-
osanguinous fluid or blood in body cavities), two FFC/SD 
[one due to lameness, another due to spontaneous acute 
bleeding (diagnosed thrombocytopenia purpura)] and six 
 FFCDIA (two due to severe necrosis/inflammation of pan-
creas), where one died suddenly, and four died suddenly 
due to pulmonary embolus (n = 3), or a tentative diagno-
sis of circulatory failure with accumulation of serosan-
guinous fluid or blood in body cavities (n = 1). Diagnoses 
were based on clinical signs and gross pathology.
Higher body weight (BW), liver weight (LW) and 
total body fat percentages (BF%) were found in FFC and 
 FFCDIA groups compared to the SD group, whereas only 
BW and BF% were higher in the FFC/SD group (Table 3). 
By macroscopic inspection, the majority of livers from 
FFC and  FFCDIA pigs were enlarged, pale red or yellow in 
color and with a bulgy appearance compared to SD. Liv-
ers from FFC/SD animals did not differ markedly from 
SD in size, color and gross appearance (Fig. 2).
Circulating biomarkers
Circulating hepatic biomarkers ALP and GLDH were 
increased in FFC and  FFCDIA groups compared to SD, 
whereas the FFC group had lower values of ALT (Table 3). 
No statistically significant difference was found for AST 
or the inflammation markers CRP and ALB. FFC and 
 FFCDIA groups had higher TG and TC than SD and FFC/
SD groups with TC further elevated in  FFCDIA compared 
to FFC. As expected, fasting GLU and FRA values were 
significantly elevated in the  FFCDIA group compared to 
the three other groups, and in addition the  FFCDIA group 
had significantly lower  KG and AUC Insulin than the other 
groups (Table  3). Furthermore,  KG in FFC was signifi-
cantly decreased compared to SD and FFC/SD, suggest-
ing impaired glucose metabolism in the two groups FFC 
and  FFCDIA. The lower  KG despite a numerically ~ two-
fold higher AUC insulin in the FFC group compared to SD 
indicates that the FFC diet and following obesity induces 
insulin resistance, which is also supported by the sig-
nificantly higher HOMA-IR in this group compared to 
SD. The additional lowering of  KG in the  FFCDIA group 
compared to the FFC group is due to the insulin deple-
tion conferred by the STZ-procedure. The only differ-
ence between FFC/SD and SD was a significantly higher 
HOMA-IR in the FFC/SD, indicating that with this index 
insulin resistance had not completely normalised yet.
Biochemical analyses of liver tissue content
Liver tissue content of triglyceride content did not differ 
between the groups (Fig. 3a), but cholesterol was higher 
in FFC and  FFCDIA groups compared to SD and FFC/SD 
groups (Fig.  3b). Regarding glycogen,  FFCDIA had lower 
liver content than FFC (Fig. 3c).
Histopathological changes
Only few and minor differences in histopathological 
changes were observed among the four liver lobes indi-
cating that the alterations were evenly distributed in the 
liver. Only slightly higher steatosis scores were found in 
SL (4 out of 43 pigs had score ≥ 1) and SM (5/43) com-
pared to DL and DM (both 0/43) (p < 0.0001), and regard-
ing inflammatory foci, DM (20/43) scored higher than 
DL (13/43) (p = 0.03). Further detailed evaluation of the 
liver lobe SM showed that steatosis, predominantly of 
macrovesicular type, was found in pigs from FFC and 
 FFCDIA groups with a centrilobular distribution, but only 
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five animals (FFC = 2,  FFCDIA = 3) had ≥ 5% parenchy-
mal involvement and no significant difference was found 
among groups (Fig. 4).
An increased content of collagen was found in FFC, 
 FFCDIA and FFC/SD groups in comparison to SD. The 
majority of these pigs had periportal fibrosis; how-
ever, four pigs (all FFC) had both periportal and ran-
domly distributed lobular fibrosis. In addition, five pigs 
(FFC = 2, FFC/SD = 1,  FFCDIA = 2) showed porto-cen-
tral bridging fibrosis (Fig. 4). None of the cases showed 
centrilobular pericellular fibrosis.
The number of lobular inflammatory foci was 
increased in FFC and  FFCDIA groups compared to both 
SD and FFC/SD (Fig. 4).
Hepatocellular cytoplasmic alterations, character-
ized by hepatocytes with pale granular cytoplasm 
(Fig. 5), were a characteristic feature in most FFC and 
 FFCDIA pigs, in contrast to both SD and FFC/SD, where 
no alterations were seen (Fig.  4). These changes were 
homogenous and widely distributed and appear to be 
similar to those seen in Ossabaw minipigs using the 
same diet [10, 12]. The changes have some resemblance 
to the hepatocellular ballooning in human NASH such 
as rounded hepatocyte enlargement and presence of 
pale cytoplasm but lack key characteristics such as 
cytoplasmatic vacuoles and Mallory–Denk bodies [25]. 
Further, no difference among groups was found for gly-
cogen staining with PAS with or without pre-treatment 
Table 3 Basic characteristics and circulating biomarkers of the four study groups
Results are presented as median and 25% and 75% quartiles. Results for BW, BF%, TC, TG, KG and AUC Insulin in diet group SD, FFC and FFC/SD have been presented 
previously [17]
ALB albumin, ALP alkaline phosphatase, ALT alanine transaminase, AST aspartate transaminase, AUC Insulin area under the curve of insulin, BF% total body fat 
percentage, BW body weight, CRP C‑reactive protein, FRA fructosamine, GLDH glutamate dehydrogenase, GLU glucose, FFC high fat/fructose/cholesterol diet group, 
FFCDIA diabetic group, FFC/SD diet‑normalization group, HOMA‑IR homeostasis model assessment of insulin resistance,  KG intravenous glucose tolerance index, LW 
liver weight, LW:BW liver weight:body weight, NA not applicable, SD lean control group, TC total cholesterol, TG triglycerides
^ Transformed
a Significantly different from SD
b Significantly different from FFC
1 n = 6 for SD, n = 13 for FFC, n = 12 for FFC/SD, n = 6 for  FFCDIA, due to catheter failure
2 n = 6 for SD, n = 13 for FFC, n = 9 for FFC/SD, n = 6 for  FFCDIA
3 n = 5 for SD, n = 13 for FFC, n = 8 for FFC/SD, n = 4 for  FFCDIA











 BW (kg) 39.00 (38.00; 41.00) 78.00 (69.00; 81.00)a 54.50 (51.00; 59.00)ab 59.50 (54.25; 64.00)ab < 0.0001^
 LW (g) 485 (458; 564) 1732 (1067; 2219)a 703 (627; 772)b 2077 (1478; 2439)a < 0.0001^
 LW:BW 0.013 (0.011; 0.015) 0.021 (0.014; 0.031)a 0.013 (0.012; 0.014)b 0.036 (0.028; 0.043)ab < 0.0001^
 BF% (%) 27.60 (24.00; 30.70) 64.20 (61.40; 67.60)a 47.30 (41.20; 50.20)ab 54.80 (52.65; 56.00)ab < 0.0001
Basic circulating biomarkers
 TC1 (mmol/L) 1.70 (1.64; 2.18) 11.94 (11.00; 13.18)a 1.89 (1.56; 2.00)b 18.91 (16.91; 27.00)ab < 0.0001^
 TG1 (mmol/L) 0.34 (0.29; 0.35) 0.63 (0.54; 0.88)a 0.36 (0.32; 0.45)b 1.45 (0.57; 1.72)ab 0.0002^
 GLU1 (mmol/L) 3.48 (3.32; 3.67) 3.72 (3.60; 3.83) 3.73 (3.47; 3.95) 15.1 (14.67; 15.45)ab < 0.0001^
 FRA1 (µmol/L) 247 (245; 271) 240 (235; 254) 246 (242; 251) 535 (452; 566)ab < 0.0001^
 KG  (min
−1)2 3.15 (2.74; 3.46) 2.11 (1.82; 2.38)a 3.2 (2.5; 3.6)b 0.74 (0.62; 0.81)a,b < 0.0001^
 AUC Insulin (pM * min)
3 12,573 (11,507; 20,683) 27,168 (17,204; 35,562) 24,032 (20,478; 28,147) 800 (616–1310)a,b < 0.0001^
 HOMA‑IR4 0.47 (0.35; 0.42) 1.11 (0.84; 1.58)a 1.59 (1.00; 1.93)a NA 0.005^
 ALB1 (g/L) 45.10 (42.70; 46.40) 42.20 (38.70; 46.20) 45.60 (42.80; 47.55) 45.45 (32.30; 46.00) 0.6
 CRP1 (ng/ml) 2320 (1840; 14,100) 3160 (2760; 6780) 4510 (2890; 7130) 7820 (3260; 19,600) 0.7^
Hepatic circulating biomarkers
 ALP1 (U/L) 62.5 (57.0; 67.0) 209.0 (143.0; 366.0)a 76.0 (61.5; 91.0)b 177.5 (139.0; 542.0)a < 0.0001^
 ALT1 (U/L) 61.00 (51.60; 67.70) 34.50 (27.20; 48.40)a 52.25 (40.75; 60.60)b 47.60 (34.40; 68.50) 0.02^
 AST1 (U/L) 33.90 (23.30; 96.10) 63.60 (25.50; 98.40) 49.65 (32.65; 59.75) 89.10 (45.40; 103.20) 0.2^
 AST:ALT1 0.64 (0.49; 1.19) 1.51 (0.85; 2.03)a 0.80 (0.70; 1.07) 1.73 (1.23; 2.3)a 0.02^
 GLDH1 (U/L) 2.30 (1.80; 3.20) 6.1 (3.20; 17.80)a 4.70 (3.35; 5.65) 15.80 (14.50; 23.40)a 0.0003^
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with diastasis (Fig.  4); in contrast to the biochemical 
analysis that showed  FFCDIA had less liver tissue glyco-
gen content than FFC.
For all TMAs, total tissue area was nearly the same 
whereas the number of lobules within that area var-
ied between pigs from seven to fifty-four (lower 
number = larger lobular diameter). The  FFCDIA group 
had larger lobular diameter than the three other groups 
(all p < 0.01), while the lobular diameter in the FFC group 
was also larger than in the FFC/SD group (p = 0.003) 
(Fig.  6). Quantification of collagen content using PSR 
revealed excessive collagen for FFC,  FFCDIA and FFC/SD 
Fig. 2 Liver gross morphology. Images show the typical liver gross morphology in each diet group. Bars (partly) visible on the sheet to the left and 















Fig. 3 Group difference in liver tissue content of lipids, cholesterol, and glycogen. Biochemical liver tissue content of a triglycerides, b cholesterol 
and c glycogen for each diet group. Bars represent median and interquartile intervals. p‑values from log transformed outcome, NS non‑significant. 
FFC high fat/fructose/cholesterol diet group, FFCDIA diabetic group, FFC/SD diet‑normalization group, SD lean control group
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compared to SD (Fig. 6). When staining with ORO, larger 
areas of lipids were found for FFC and  FFCDIA groups 
compared to both SD and FFC/SD groups (Fig. 6); how-
ever, a large degree of heterogeneity was seen within the 
groups (Fig. 7). IHC staining for Iba1 indicated increased 
number of macrophages in both FFC and  FFCDIA groups 
as compared to SD and FFC/SD groups (Fig. 6). Figure 8 
shows typical examples of histopathological findings for 
each group.
Associations between circulating biomarkers 
and histopathology
Regarding associations between circulating biomark-
ers and parametric histopathological variables (Table 4), 
lipid parameters TC and TG were associated with both 
ORO-VIS and Iba1-VIS, whereas GLDH was associated 
with ORO-VIS and ALP to Iba1-VIS.
Comparison between circulating biomarkers and cat-
egorical histopathological features (Table  4), revealed 
association between both circulating lipids TG and TC 
and the inflammation score and especially the CA score. 
For circulating hepatic markers, associations were seen 
between most markers and the CA score, fibrosis score, 
and inflammation score.
Associations between histopathological findings
For the histopathological features applied, the cytoplas-
mic alteration score was associated with all other features 
except the PAS-score (Table  5). In fact, the PAS-score 
showed no association to any of the other histopathologi-
cal findings. Scores for both fibrosis and inflammatory 
foci also had a strong association to the quantification of 
fibrosis (PSR-VIS) (Table 5).
Associations between biochemical analyses of liver tissue 
content and histopathological findings
As expected, tissue triglyceride content showed a strong 
association to the quantification of lipid (ORO-VIS) and 
glycogen content was strongly associated to the PAS 
score (Table  6), even though the PAS ± diastasis stain-
ing technique can be challenging in terms of accuracy. 
In addition, a significant association was found between 
liver tissue content of cholesterol and most histopatho-
logical findings, especially CA score.
Intra-assay and intra-observer variations
Lastly the intra-assay coefficients of variance (CV), for 
all three biochemical tissue content analyses were below 










Fig. 4 Difference between groups for histopathological scores. Scores for a steatosis, b fibrosis, c inflammation, d cytoplasmic alterations and e 
PAS‑positive staining for each diet group. FFC high fat/fructose/cholesterol diet group, FFCDIA diabetic group, FFC/SD diet‑normalization group, SD 
Lean control group
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Fig. 5 Examples of cytoplasmic alterations in hepatocytes characterized by hepatocytes with pale, granular appearance. a Normal hepatocytes 
from lean control animal (SD). b, c Hepatocytes with cytoplasmic alterations both from animals fed high fat/fructose/cholesterol diet (FFC). Scale 
bar 25 µm. Hematoxylin and eosin staining
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inflammatory foci, cytoplasmic alterations and PAS posi-
tive cells the assigned score differed no more than one 
when performed by the same observer. No intra-observer 
difference was found for steatosis score.
Discussion
This study demonstrated that Göttingen Minipigs fed 
a high fat diet with fructose and cholesterol became 
obese and developed hepatomegaly with hepatic fibrosis, 
inflammation and cytoplasmic alterations when com-
pared to animals fed a normal diet. However, only few 
animals developed marked steatosis, and hepatocellular 
hydropic degeneration (ballooning) and Mallory–Denk 
bodies were not observed in any animal. Streptozotocin-
induced diabetes did not exacerbate the changes in cir-
culating biomarkers or hepatic histopathology, compared 
to non-diabetic animals fed a similar diet. The group 
changed to standard diet for 6  months had no hepatic 
changes, except from excess collagen deposition.
The large number of animals, the more than 1-year 
study period, and the comprehensive investigation of 
several parameters in the present study strengthen the 
characterization of the hepatic changes in obese Göt-
tingen Minipigs with and without diabetes.
As expected, the FFC and  FFCDIA groups developed 
obesity with higher BW, BF% and dyslipidemia (defined 
as increased plasma TG and TC) compared to the two 
groups fed standard diet. The  FFCDIA group had signifi-
cantly higher levels of fasting GLU and FRA confirming 
hyperglycemia. Plasma ALP and GLDH were increased, 
whereas an increase in circulating concentrations of ALT 
and AST was not found, in fact plasma ALT was lower in 
FFC pigs compared to SD and FFC/SD. Studies of Ossa-
baw minipigs on the same diet also found no difference 
a b
c d
Fig. 6 Parametric histopathological assessment of lipid, collagen and inflammation plus difference in lobules/TMA between groups. Differences 
between diet groups. a Quantification of lipid on Oil red O staining. b Quantification of collagen as a measure for fibrosis on Picro‑sirius red staining. 
c Quantification of anti‑Iba1 immuno‑positive macrophages as a measure of inflammation. d Difference between groups in the number of lobules 
per TMA from the lobe SM. Bars represent median and interquartile intervals. p‑values are from log transformed outcome. FFC high fat/fructose/
cholesterol diet group, FFCDIA diabetic group, FFC/SD diet‑normalization group, SD Lean control group, SM lobus hepatis sinister medialis, TMA tissue 
micro arrays
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in ALT compared to control animals, whereas AST was 
increased. However, in pigs, GLHD is considered a more 
reliable marker of acute liver damage, as compared to 
ALT, which is non-specific in pigs [26]. Also, in human 
patients with NAFLD, ALT values have not been found 
to correlate with the degree of histopathological changes 
[27]. Table  7 provides an overview of relevant NAFLD/
NASH characteristics including selected circulating bio-
markers from human and pig studies.
The LW was highly increased in both FFC and  FFCDIA 
groups compared to SD, and despite elevated liver con-
tent of cholesterol in both groups, unexpectedly no 
statistically significant differences were found for triglyc-
erides liver content among the four groups.
Furthermore, the degree of histopathological altera-
tions was less than expected, especially regarding stea-
tosis, despite the presence of metabolic disturbances 
indicated by the changes in circulating markers. Few 
animals displayed more than 5% macrovesicular stea-
tosis which is a criterion for the diagnosis of NAFLD in 
humans [28, 29]. Rodent models on a high fat diet usu-
ally report abundant macro- and microvesicular steatosis 
[30, 31], but previous studies in Ossabaw minipigs on the 
same diet (5B4L) also reported lack of macrovesicular 
steatosis, despite extensive liver injury [10, 12]. Others 
have reported extensive microvesicular steatosis with lit-
tle or no presence of macrovesicular steatosis in pigs on 
high fat plus high cholesterol or high sucrose diets [11, 
13]. Microvesicular steatosis was rarely seen in our pigs, 
and the low level of both types of steatosis is consistent 
both with the biochemical analysis and the quantification 
of lipid on ORO stained slides. This modest accumulation 
of lipids in the liver could reflect the fact that the liver in 
pigs, in contrast to humans and rodents, is not the pri-
mary site of de novo lipogenesis [32]. Also, the overnight 
fasting period before termination might have had some 
influence on the lipid content in the liver. However, so 
far it is unclear what is responsible for the significantly 
increased LW in FFC and  FFCDIA groups and it needs to 
be clarified if hepatocyte hypertrophy or hyperplasia is 
the reason for the present hepatomegaly.
Hepatocellular ballooning, another criterion for the 
diagnosis of human NASH, was not seen in our study, 
but extensive cytoplasmic alterations in hepatocytes were 
present in FFC and  FFCDIA groups. It was speculated that 
these alterations could be caused by an accumulation of 
Fig. 7 Heterogeneity of Oil red O staining of lipid within the diet groups. Six representative examples of lipid staining from six different animals 
within each group showing different patterns of lipid distribution. Scale bar 2.5 mm. a SD Lean control group. b FFC high fat/fructose/cholesterol 
diet group. c FFCDIA diabetic group. d FFC/SD diet‑normalization group
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glycogen. Glycogenic hepatopathy is a condition with 
massive cytoplasmic deposition of glycogen in hepato-
cytes leading to hepatomegaly, and is mostly seen in 
patients with poorly controlled type 1-diabetes. The 
diagnosis is confirmed with liver biopsies and staining 
for glycogen with PAS [33]. In this study, staining for gly-
cogen with PAS however did not show correlation with 
CA in either  FFCDIA or FFC, and the  FFCDIA group also 
showed decreased glycogen content in their liver tissue 
in comparison to the FFC group. Instead a strong asso-
ciation between CA and cholesterol content in the liver 
persisted, and perhaps CA could reflect a functional 
adaptation to the increased cholesterol load. In humans, 
it has recently been suggested that dietary cholesterol 
activates the hepatic stellate cells thereby promoting 
fibrosis especially if hepatocyte uptake or biliary excre-
tion of cholesterol is inhibited [34].
Mallory–Denk bodies is a characteristic feature of 
NASH in humans, but can be difficult to identify and 
often additional IHC staining has to be performed, e.g., 
using ubiquitin or cytokeratin 8/18 antibody. Lackner 
et  al. found that CK 8/18 was diminished or absent in 
ballooned hepatocytes compared to normal hepato-
cytes. They also found that Mallory–Denk bodies were 
not always present [25]. Others suggest double immu-
nohistochemical staining of CK8/18 and ubiquitin for 
Fig. 8 Panel of representative histopathological findings in the different diet groups. 1st row: SD + FFC/SD normal hepatocytes without 
cytoplasmic alterations (CA) (CA score 0). FFC Hepatocytes with cytoplasmic alterations (CA score 3).  FFCDIA Hepatocytes with cytoplasmic 
alterations (CA score 3) plus macrovesicular steatosis (steatosis score 1). Hematoxylin and eosin (HE) staining, magnification ×40. 2nd row: SD 
Normal collagen septa surrounding the lobules (fibrosis score 0). FFC Periportal and perisinusoidal fibrosis (fibrosis score 2). FFC/SD Portal/periportal 
fibrosis seen as excessive collagen deposition along septa and portal areas (fibrosis score 1C).  FFCDIA Bridging fibrosis with collagen deposition from 
portal area to central vein (fibrosis score 3). Picro‑sirius red (PSR) staining, magnification ×5. 3rd row: SD + FFC/SD normal background staining 
of macrophages. FFC + FFCDIA Increased staining of macrophages compared to normal. Immunochemical staining with antibodies against Iba1, 
magnification ×20. 4th row: Periodic‑acid Schiff (PAS) staining for glycogen SD ‘+’ (PAS positive score 1). FFC ‘++’ (PAS positive score 2). FFC/
SD ‘−’ (PAS positive score 0).  FFCDIA ‘++’ (PAS positive score 2). PAS staining without pretreatment with diastasis, magnification ×20. 5th row: 
SD + FFC + FFC/SD + FFCDIA Pretreatment with diastasis for degradation of glycogen before staining with periodic‑acid Schiff (PASd). Used as 
control for intensity of glycogen (PAS) staining without pretreatment, magnification ×20. SD Lean control group, FFC high fat/fructose/cholesterol 
diet group, FFC/SD diet‑normalization group, FFCDIA diabetic group
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the optimal detection of hepatocellular injury in human 
liver [35]. In some mouse models of NASH, Mallory–
Denk bodies have been reported morphologically [30, 36, 
37], but until now no previous studies with pigs [10–12] 
or other rodent species [31, 38] have identified Mal-
lory–Denk bodies along with hepatocellular ballooning. 
Immunohistochemical staining of CK8/18 or ubiquitin 
in liver tissue of porcine NAFLD/NASH models has not 
been reported. However, in a mouse model of NAFLD/
NASH staining for CK8/18 has been used [31] and found 
less or absent staining in hepatocytes with ballooning.
The predominantly periportal fibrosis seen in our 
minipigs is coherent with findings in Ossabaw minipigs 
[12]. This is in contrast to humans where perisinusoidal 
fibrosis around the central vein dominates and peripor-
tal fibrosis occurs only in later disease stages. A possible 
explanation for this peripheral deposition of collagen 
could be the localization of the porcine hepatic stellate 
cells. These cells are responsible for collagen produc-
tion when activated and heterogeneity of stellate cells 
in the porcine liver was described by Wake et  al. [39] 
who found that desmin positive stellate cells were most 
abundant in the peripheral regions of the classical lob-
ules. Interestingly, two subtypes of NAFLD have been 
described in pediatric patients; type 1 resembles ‘adult’ 
NAFLD whereas type 2 is characterized by steatosis, por-
tal inflammation and portal fibrosis [40] and is known to 
be the most prevalent type in children. The mechanism 
behind this pediatric portal fibrosis is unknown but per-
haps a common pathway for portal fibrosis in children 
and pigs exist. The hepatic inflammation seen in FFC and 
 FFCDIA groups was not a reflection of a systemic inflam-
matory state as the circulating inflammatory markers 
Table 4 Associations between the circulating biomarkers and the histopathological findings
All response variables were transformed for normal distribution of residuals
ALP alkaline phosphatase, ALT alanine transaminase, AST aspartate transaminase, CRP C‑reactive protein, CA cytoplasmic alterations, GLDH glutamate dehydrogenase, 
Iba1‑VIS quantification of macrophages on Iba1 immunohistochemical stain, ORO‑VIS quantification of lipid on oil red O stain, PAS positive periodic acid Schiff stain for 
glycogen, PSR‑VIS quantification of collagen on picro‑sirius red stain, TC total cholesterol, TG triglycerides
Data presented as p‑value  (R2)
a Significant result
Elements ORO-VIS PSR-VIS Iba1-VIS Steatosis score Fibrosis score Inflammation score CA score PAS score
Biomarkers
 TC < 0.0001 (0.41)a 0.01 (0.17)a < 0.0001 (0.45)a 0.05 (0.16)a 0.2 (0.14) 0.02 (0.26)a < 0.0001 (0.56)a 0.3 (0.10)
 TG 0.001 (0.28)a 0.01 (0.17)a 0.0007 (0.28)a 0.2 (0.10) 0.04 (0.22)a 0.009 (0.29)a < 0.0001 (0.49)a 0.4 (0.09)
 ALP 0.003 (0.23)a 0.002 (0.25)a 0.0006 (0.29)a 0.11 (0.12) 0.04 (0.22)a 0.008 (0.30)a < 0.0001 (0.55)a 0.03 (0.24)a
 ALT 0.2 (0.06) 0.4 (0.02) 0.005 (0.20)a 0.02 (0.21)a 0.6 (0.05) 0.5 (0.07) 0.1 (0.15) 0.1 (0.15)
 AST 0.02 (0.16)a 0.01 (0.17)a 0.2 (0.05) 0.1 (0.13) 0.01 (0.27)a 0.2 (0.13) 0.03 (0.23)a 0.9 (0.02)
 AST:ALT 0.0005 (0.31)a 0.0001 (0.35)a 0.006 (0.20)a 0.02 (0.20)a < 0.0001 (0.47)a 0.008 (0.30)a 0.0004 (0.42)a 0.5 (0.07)
 GLDH 0.001 (0.27)a 0.007 (0.19)a 0.003 (0.22)a 0.2 (0.10) 0.002 (0.35)a 0.03 (0.23)a 0.0002 (0.44)a 0.7 (0.05)
 CRP 0.7 (0.01) 0.6 (0.01) 0.2 (0.04) 0.5 (0.03) 0.8 (0.03) 0.9 (0.02) 0.7 (0.04) 1 (0.00)
Table 5 Associations between the categorical and the parametric histopathological findings
Elements Steatosis
score
Fibrosis score Inflammatory 
foci score









CA score 0.005^a 0.006^a < 0.0001^a
PAS score 0.4^ 0.3^ 0.9^ 0.3^
PSR-VIS 0.02 (0.18)a < 0.0001 (0.52)a < 0.0001 (0.46)a < 0.0001 (0.48)a 0.8 (0.03)
Iba1-VIS 0.1 (0.11) 0.04 (0.19)a 0.01 (0.24)a < 0.0001 (0.50)a 0.7 (0.04) 0.0003 (0.27)a
ORO-VIS 0.002 (0.29)a 0.03 (0.21)a 0.002 (0.33)a 0.0002 (0.41)a 0.2 (0.12) 0.08 (0.08) 0.02 (0.14)a
PSR‑VIS, Iba1‑VIS and ORO‑VIS as outcome were log‑transformed
CA cytoplasmic alterations, Iba1‑VIS quantification of macrophages on Iba1 immunohistochemical stain, ORO‑VIS quantification of lipid on oil red O stain, PAS positive 
periodic acid Schiff stain for glycogen, PSR‑VIS quantification of collagen on picro‑sirius red stain
Data presented as p‑value  (R2)
^ p‑value from Fisher’ exact test
a Significant result
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CRP and ALB showed no difference between the four 
groups.
Interestingly, the FFC/SD group also differed from 
SD in terms of fibrosis, despite being fed the same 
standard diet for the last 6 months. This indicates that 
fibrosis developed in the first 7 months of high fat/high 
cholesterol-feeding and either did not progress further 
during the 6 months of healthy dieting, or maybe even 
regressed.
Diabetes did not exacerbate the hepatic histopathology, 
although the  FFCDIA pigs had substantial dyslipidemia 
with elevated levels of TC and TG and a liver tissue cho-
lesterol content exceeding that of the FFC group. Previ-
ous unpublished studies indicated that 2% cholesterol 
was needed in order to achieve the desired elevated 
level of circulating total cholesterol in normal minipigs, 
whereas diabetic minipigs reached the same level on a 
1% cholesterol diet, which was also the case here. Six dia-
betic pigs were terminated prematurely nearly reducing 
the group by half, which could have led to lack of statis-
tical power when comparing the  FFCDIA group with the 
FFC group.
Our diabetic animals had a type 1-like diabetes pheno-
type and were treated with long acting insulin analogue 
to keep blood glucose around 15 mM. A lower incidence 
of NAFLD has been found in patients with type 1 dia-
betes compared to patients with type 2 diabetes, and it 
is suggested that insulin treatment’s inhibiting effect on 
lipolysis is responsible for the decreased level of free 
fatty acids accumulating in the liver. Insulin resistance 
induced by excessive caloric intake is also known to play 
Table 6 Associations between  the  biochemical analyses 
of liver tissue content and the histopathological findings
Iba1‑VIS quantification of macrophages on Iba1 immunohistochemical stain, 
ORO‑VIS quantification of lipid on oil red O stain, PAS positive periodic acid Schiff 
stain for glycogen, PSR‑VIS quantification of collagen on picro‑sirius red stain
Data presented as p‑value  (R2)
^ Transformed
a Significant result
Variable Triglycerides^ Cholesterol^ Glycogen^
Parametric findings
 ORO‑VIS (lipid) < 0.0001 (0.59)a 0.0004 (0.27)a 0.0001 (0.32)a
 PSR‑VIS (collagen) 0.4 (0.04) < 0.0001 (0.34)a 0.6 (0.01)
 Iba1‑VIS (inflamma‑
tion)
0.3 (0.03) < 0.0001 (0.39)a 0.9 (0.001)
Categorical scores
 Steatosis 0.006 (0.17)a 0.004 (0.24)a 0.1 (0.09)
 Fibrosis 0.4 (0.07) 0.006 (0.27)a 0.6 (0.05)
 Inflammation 0.3 (0.1) 0.0002 (0.39)a 0.9 (0.01)
 Cytoplasmic altera‑
tions
0.98 (0.00) < 0.0001 (0.73)a 0.2 (0.11)
 PAS positive 0.005 (0.29)a 0.4 (0.07) < 0.0001 (0.75)a
Table 7 Comparison of selected elements of porcine models of NAFLD/NASH and human NAFLD/NASH
Selected histopathological elements, biochemical analyses of liver tissue content of lipids and circulating biomarkers from human and different pig studies. The study 
of Li et al. [43] is not included as relevant information for comparison is missing
ALT Alanine transaminase, AST Aspartate transaminase, – Not mentioned
a Only present in Sudan III staining
b Not typical human‑like hydropic degeneration (ballooning)
c Given as cholesterol esters





















Steatosis, macro Yes Yes Minimal 3 out of 7 No No –
Steatosis, micro No No No Yes – Yesa Yes
Fibrosis, perisinusoidal Yes/No No Yes Yes Yes – No
Fibrosis, portal No Yes Yes Yes Yes Yes No
Inflammation, lobular Yes No Yes 4 out of 7 No Yes Yes
Inflammation, portal No Yes Yes No – Yes –
Hepatocellular ballooning Yes No No Yesb Yesb No Yesb
↑ triglycerides liver content – – No Yes No – Yes
↑ cholesterol liver content – – Yes – Yes – Yesc
↑ ALT Yes/No Yes/No No No No Yes No
↑ AST – Yes/No No Yes Yes Yes Yes
Hypercholesterolemia – – Yes Yes Yes Yes Yes
Hypertriglyceridemia Yes Yes Yes Yes Yes1 Yes No
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a role in hepatic lipid accumulation and the develop-
ment of NAFLD. Only  FFCDIA had elevated fasting blood 
glucose, but insulin resistance can be present in muscle 
and liver without hyperglycemia in human patients with 
NAFLD [41]. Although insulin resistance was not directly 
assessed in the current study,  KG, AUC insulin and HOMA-
IR values indicated that FFC and likely  FFCDIA animals 
were insulin resistant on a whole-body level, but since no 
profound steatosis was present, hepatic insulin resistance 
is less likely to be a major factor in this model.
A limitation to this study was, that 11 animals ended 
the study prematurely and necropsy reports mentioned 
enlarged pale livers in all FFC (n = 2) and  FFCDIA (n = 6) 
pigs, but no further analyses were performed. It could be 
speculated that these excluded animals especially from 
the  FFCDIA group may have exhibited more pronounced 
hepatic changes thus biasing our results as only animals 
with less pronounced changes were able to complete the 
full study period. Another limitation is that no liver biop-
sies were taken at different time points during the study, 
especially before the FFC/SD group was changed to 
standard diet, making it difficult to conclude if the differ-
ences between FFC and FFC/SD were due to lack of pro-
gression or regression of marked changes already present 
at the intervention time point.
Overall, this diet-induced obese Göttingen Minipig 
model with or without diabetes poses some challenges 
in terms of translatability with human NASH, because 
some of the cardinal characteristics (abundant steatosis, 
hepatocellular ballooning and Mallory–Denk bodies, and 
zone 3 fibrosis) were missing. However, to explain some 
of the rather unexpected elements of this model, further 
studies are needed. Additional staining with e.g. CK8/18, 
ubiquitin, p62 or sonic hedgehog markers could be per-
formed in order to validate if Mallory–Denk bodies (or 
their precursors) were present in this minipig model. 
Moreover, evaluation of serum CK8/18 may elucidate 
if depletion at tissue level could give as consequence an 
increase in the circulation of keratin fragments that are 
major components of Mallory–Denk bodies [42]. By elu-
cidating the pathological pathways perhaps combined 
with gene expression and electron microscopy, the mech-
anisms leading to CA in hepatocytes and the portal/peri-
portal fibrosis could be further clarified.
Conclusion
In conclusion, a diet-induced obese Göttingen Mini-
pig model with and without diabetes has been evalu-
ated as a model of human NAFLD including NASH. 
Even though fibrosis, inflammation and cytoplas-
mic alterations occurred, cardinal histopathological 
characteristics such as hepatocellular ballooning and 
abundant steatosis were lacking despite the presence of 
overt obesity and dyslipidaemia. Furthermore, diabetes 
did not seem to exacerbate the hepatic changes devel-
oped by the high fat/fructose/cholesterol diet alone. 
The limited presence of key human-relevant patho-
logical hepatic findings and variation in the model, 
limits its use in preclinical research without further 
optimisation.
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